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Correspondence should be addressed to Errol B. De Souza, Ph.D., Neuroscience Branch, Addiction Research Center, National Institute on Drug Abuse, P.O. Box 5 180, Baltimore, MD 2 1224. 0270-6474/87/010088-13$02.00/O Corticotropin-releasing factor (CRF), a 4 1 -amino-acid peptide originally isolated from ovine hypothalami (Vale et al., 198 l) , stimulates the release of proopiomelanocortin (POMC)-derived peptides from the anterior and intermediate lobes of the pituitary gland (reviewed in Vale et al., 1983; . More recently, the amino acid sequences of both rat and human (Shibihara et al., 1983 ) CRF have been elucidated and were found to be identical to one another, but to differ from ovine CRF by 7 amino acid residues. In addition to its endocrine role at the pituitary, CRF has been demonstrated to have a broad extrahypothalamic distribution in the CNS (Olschowka et al., 1982; Cummings et al., 1983; Swanson et al., 1983) , and to produce a wide spectrum of autonomic (Brown et al., 1982; Fisher et al., 1983; Tache et al., 1983) and behavioral (Britton et al., 1982; Morley and Levine, 1982; Sutton et al., 1982; Sirinathsinghji et al., 1983; Veldhuis and De Wied, 1984) effects. The results of these studies have led to the suggestion that CRF may act as a neurotransmitter or neuromodulator in the CNS, where it appears to play a role in the integration of the organism's responses to stress. A neurotransmitter role for CRF in the rat CNS is further supported by several findings at the cellular level, including its release from brain slices in a calcium-dependent manner following potassium stimulation (Smith et al., 1986) , the ability of CRF to alter neuronal firing rates following iontophoretic application (Aldenhoff et al., 1983; Eberly et al., 1983; Valentino et al., 1983) , and its ability to promote the formation of CAMP (Wynn et al., 1984; Chen and Bilezikjian, 1985) . Recently, we and others have reported the autoradiographic identification and characterization of specific binding sites for iodine-125labeled analogs of ovine CRF in rat (De Souza et al., 1984b , 1985a Wynn et al., 1984; De Souza and Kuhar, 1986a, b) , monkey (De Souza and Kuhar, 1986a, b) and human (De Souza and Kuhar, 1986b) brain; however, specific binding sites for endogenous CRF remain to be identified and characterized in rat brain. In the present study, we have used a stable, iodine-125-labeled analog of the endogenous ligand lZ51-TyrO rat/human CRF (lZSI-rCRF) to examine in detail the kinetic and pharmacological characteristics and regional distribution of CRF receptors in rat brain membrane homogenates.
Materials and Methods
Animals. Male Sprague-Dawley rats (Madison, WI) weighing 175-250 gm were used throughout this study. Animals were housed in a lightand temperature-controlled room, with food and water available ad libitum.
Materials. Iodinated rat CRF (specific activity, 2200 Ci/mmol) was obtained from New England Nuclear (Boston, MA); unlabeled rat and ovine CRF were purchased from Peninsula Laboratories (Belmont, CA). Figure I . Effect of pH on 1251-Tyr0 rat/ human CRF binding to rat olfactorv bulb membranes. +-TyrO rat/human CRF was incubated in 50 mM Tris-HCl. 10 mM MgCI,, 2 mM EGTA, 1O-4 ; bacitracin, and 100 kallikrein units/ml aprotinin for 120 min at room temperature with a crude mitochondrial/synaptosomal membrane preparation at pH values ranging from 5.5 to 8.2. Each point is the average of 3 or 4 determinations, which differed by less than 10%.
All of the CRF fragments, analogs, and vasoactive intestinal peptide, arginine vasopressin, angiotension II, and His1,NleZ7 growth hormone-, releasing factor (l -32)NH, used in displacement experiments were synthesized and generously provided by Dr. Jean Rivier ofthe Salk Institute Peptide Biology Laboratory (La Jolla, CA). All other standard reagents were purchased from Sigma (St. Louis, MO); guanosine S-triphosphate (GTP) and 5'-guanylimidodiphosphate (GppNHp) were used as the sodium salts.
Tissue preparation. Rats were killed by decapitation, and brain regions of interest were dissected as previously described (Glowinski and Iversen, 1966) , weighed, and placed in 30 volumes of ice-cold buffer (50 mM Tris-HCl, 10 mM MgCl,, 2 mM EGTA, and 0.32 M sucrose; pH 7.2). All assays were run using freshly dissected tissue, except for assays of anterior pituitary tissue; anterior pituitaries were collected on dry ice and stored at -70°C until assayed. The tissue was homogenized by 10 passes of a Teflqn pestle homogenizer. In routine studies, the homogenate was centrifuged at 4°C for 10 min at 1000 x g; the resulting pellet (PI) was discarded and the supematant (S,) was recentrifuged at 4°C for 30 min at 20,000 x g. The resulting supematant (SZ) was discarded and the pellet (PZ) was saved. Subcellular fractionation studies were carried out as previously described (Whittaker and Barker, 1972) ; the P, pellet was saved and the supematant (S,) from the secondcentrifugation was recentrifuged at 4°C for 60 min at 100,000 x g, the supematant (S,) was discarded and the pellet (P,) was saved. All pellets were resuspended in 50 mM Tris-HCl, 10 mM MgCl,, 2 mM EGTA, 0.1% BSA, aprotinin (100 kalhkrein units/ml) and 0.1 mu bacitracin, pH 7.2, to a final protein concentrafion of0.254.5 mg/ml, using a Brinkman polytron (Westbury, NY) set at 5 for 20 sec. Final protein concentration of each membrane preparation was determined by the method of Lowry et al. (195 1) using BSA as a standard.
'25Z-rCRF binding assay. One hundred microliters of the membrane suspension was added to 1.5 ml polypropylene microtubes (Sarstedt, W. Germany) containing 100 ~1 of an 12+rCRF solution (approximately 30,000 cpm) and 100 ~1 of the incubation buffer or an appropriate concentration of unlabeled rat/human CRF (rCRF) or other competing peptide. Nonspecific binding was determined in the presence of 1 PM rCRF. The reaction was allowed to proceed for 2 hr at room temperature. The tissue was separated from the incubation medium by centrifugation in a Beckman microfuge for 3 min at 12,000 k g. The resulting pellet was washed gently with 1 ml of ice-cold PBS, pH 7.2, containing 0.01% Triton X, and the contents were recentrifuged for 3 min at 12,000 x g. The supematant was aspirated and the radioactivity of the pellet was measured in a gamma counter at 80% efficiency.
RP-HPLC analysis of CRF so/i&ions and tissue extracts. Aliquots of an Y-rCRF solution (approximately 3000 cpm), the supematant from the first centrifugation of a sample assayed as described above, and an acid extract (20% acetonitrile in 0.1% trifluoroacetic acid) from the final pellet of the same sample were analyzed by reversed-phase high-performance liquid chromatography (RP-HPLC) on a Waters C,, P-Bondapak column (4.6 mm x 30 cm) equilibrated with solution A (20% acetonitrile in 0.1% trifluoroacetic acid) at a flow rate of 1 .O ml/min; 10 min after sample injection, a linear gradient to 85% solution B (80% acetonitrile in 0.1% trifluoroacetic acid) over 65 min was initiated. Unlabeled rCRF was detected by absorbance at 220 nm.
Data analysis. The Y-rCRF bindina data were analvzed bv the computer program EBDA (McPherson, 1<83), which pro;ides mitial estimates of equlibrium binding parameters by Scatchard, Hill, and EadieHofstee analysis and then produces a file for the nonlinear curve-fitting program LIGAND (Munson and Rodbard, 1980) , which gives final parameter estimates.
Results
Preliminary studies to optimize and characterize lz51-rCRF in olfactory bulb membranes On the basis of previous autoradiographic localization studies of the distribution of binding sites for an iodine-12%labeled Figure 2 . Effect of ionic strength of Tris-HCl buffer on 1251-Tyr0 rat/human CRF binding to rat olfactory bulb membranes. '251-Tvr0 rat/human CRF was incubated for 120 min at room temperature in 25-170 mM Tris-HCl buffer, pH 7.2, containing 10 mM MgCl,, 2 mM EGTA, 10m4 M bacitracin, and 100 kallikrein units/ml aprotinin with a crude mitochondrial/synaptosomal membrane preparation. Each point is the average of 3 or 4 determinations, which varied by less than 10%. analog of ovine CRF in rat brain (De Souza et al., 1984b , 1985a De Souza and Kuhar, 1986a, b) and preliminary results of regional homogenate assays, the binding l*SI-rCRF was characterized in crude mitochondrial/synaptosomal (PJ membrane preparations of rat olfactory bulb, a region with a high concentration of CRF binding sites.
In all experiments, specific binding of 1251-rCRF to rat brain membranes was defined as binding displaced by 1 FM unlabeled rCRF. '251-rCRF binding was sensitive to the pH ( Fig. 1 ) and ionic strength (Fig. 2) of the incubation buffer. Optimal binding was observed over a relatively broad pH range of 6.1-7.3; the binding was decreased by 40 and 65% at pH 5.6 and 8.1, respectively ( Fig. 1) . The sensitivity of 1251-rCRF binding to the ionic strength of the buffer in the range of 25-170 mM Tris-HCl buffer is shown in Figure 2 ; the binding was optimal at 50 mM Tris-HCl and declined precipitously at higher ionic strengths. The substitution of a sodium phosphate buffer was found to have no effect on the binding (data not shown). The binding of 12SI-rCRF was dependent on the presence of magnesium ions; linear increases in specific binding were observed up to a concentration of 10 mM MgCl, (Fig. 3 ). This effect appeared to be specific to magnesium, as the presence of up to 12.5 mM NaCl had no effect on binding, and only slight increases were observed in the presence of a comparable concentration of CaCl, (Fig. 3) . Incubation of varying concentrations of membranes with 1251-rCRF indicated that binding of the radioligand was linear with protein concentration to approximately 100 pg/tube (Fig. 4) ; higher protein concentrations resulted primarily in an increase in the nonspecifically bound rZ51-rCRF. Tissue that was boiled for 5 min before incubation showed no detectable specific '*VrCRF binding. On the basis of these preliminary experiments, all subsequent assays were routinely performed in 50 mM TrisHCl buffer containing 10 mM MgCl, (pH 7.2 at 23"C), and the incubations were carried out with a membrane protein concentration of 25-50 pg/tube. In addition, the protease inhibitors bacitracin (1 O-4 M) and aprotinin (100 kallikrein units/ml) were included in the incubation buffer to minimize degradation of the peptide and/or receptor during the course of the assay. Under these assay conditions, specific binding represented 70-75% of total 12SI-rCRF binding.
To determine whether the assay conditions described above were effective in limiting degradation of 1251-rCRF, and to ascertain that membrane-bound radioactivity represented intact 1251-rCRF, analytical RP-HPLC profiles of the added ligand, the postincubation supematant, and extracted membrane-bound ligand were compared. After 120 min of incubation, the r251-rCRF in the incubation medium and *251-rCRF extracted from the membrane pellet eluted as a single peak with fresh rZ51-rCRF ( Fig. 5) , thereby demonstrating the stability of the radioiodinated ligand under routine assay conditions, as well as confirming the identity of the membrane-bound rZSI-rCRF. The subcellular distribution of 1251-rCRF binding sites was examined by comparing binding levels observed in pellets obtained from successive fractionation steps. The total number and density of specific rZ51-rCRF binding sites were greater in the crude mitochondrial/synaptosomal pellet (P,) than in the P, 'WTyr" rat/human CRF binding to rat olfactory bulb as a function of the membrane protein concentration. 1251-Tyr0 rat/human CRF was incubated for 120 min at room temperature in standard incubation buffer with increasing concentrations of crude mitochondriakynaptosomal membranes. Each point is the average of 4 determinations, which varied by less than 10%. fraction representing nuclei and cellular debris (Table 1) . No significant 1251-rCRF binding was found in the microsomal pellet (P,). This crude subcellular distribution of binding sites for lz51-rCRF is consistent with a localization of binding to membranes derived from nerve terminals.
Kinetics of lZ51-rCRF binding to receptors The time courses of lZ51-rCRF association to rat olfactory bulb membranes are shown in Figure 6 . The association rate of lZ51-rCRF was temperature-dependent and exhibited pseudo-firstorder kinetics. At room temperature (23"Q the binding increased with time to reach a steady state after 90 min and equilibrium binding conditions persisted till at least 3 hr of incubation. The rate of association was more rapid at 37°C (K, = 1.9 x lo9 M-I min-I) than at room temperature (K, = 5.2 x lo8 M-I min-I) but this increased rate of association at 37°C was accompanied by a substantially lower level and duration of equilibrium-specific binding of lZ51-rCRF. The decrease in lZ51-rCRF binding with longer periods of incubation at 37°C probably resulted from a more rapid degradation of the ligand, as evidenced by the proportionally higher level of nonspecific binding at this temperature (data not shown). Negligible amounts of specific 1251-rCRF binding were observed at 4"C, with incubation periods lasting up to 2 hr.
The time course of lZ51-rCRF dissociation from rat olfactory bulb membranes is shown in Figure 7 . lZ51-rCRF binding decreased as a function of time following the addition of 1 pM unlabeled rat CRF, demonstrating the reversibility of the binding reaction. A plot of ln(BIB,) against time (see inset in Fig.  7 ) resulted in a monophasic profile at both 23 and 37°C. The rate of dissociation of lZ51-rCRF was temperature-dependent, with more rapid dissociation observed at 37°C (K-, = 0.32 min-I) than at 23°C (Km, = 0.007 min-I), corresponding to apparent half-times of 2.2 and 99 min, respectively.
1251-rCRF binding characteristics at equilibrium
The concentration-dependent equilibrium binding of *251-rCRF to rat olfactory bulb membranes was examined and is shown in Figure 8A . Specific lZ51-rCRF binding was saturable and Scatchard analysis of the saturation data (Fig. 8B) indicates that the binding is of high affinity, with an apparent equilibrium dissociation constant (KJ of 192 PM and a maximum number of binding sites (B,,,) of 243 fmol/mg protein.
In the range of ligand concentrations (0.05-l nM) used in our saturation studies, lZ51-rCRF appears to bind to a single class of sites, as indicated by both the straight line obtained from the Table 1 . 1251-Tyr0 rat/human CRF binding to subcellular fractions of rat olfactory bulb Specific 1251-Tyr0 rat/ human CRF bound Olfactory bulb fraction (fmol/mg protein) 1000 x g pellet (P,) 17.1 * 0.2 20,000 x g pellet (PJ 31.0 * 1.0 100,000 x g pellet (P,) 0
Crude fractions of rat olfactory bulb were prepared as described in Materials and Methods. Aliquots of tissue comprising the various fractions were incubated with 35 PM '2SI-TyP rat/human CRF for 120 min at room temperature in the absence (total) or presence (blank) of 1 NM unlabeled rat CRF. At the concentration of ligand used in the fractionation studies, approximately 15% of the total 'zSI-TyP rat/human CRF binding sites were occupied. The data are based on 5 determinations from a representative experiment (mean * SEM), which were confirmed by 2 independent repetitions of the experiment and were found to vary less than 10% from each other. Figure 4 . Effects of cations on 1251-Tyti rat/human CRF binding to rat olfactory bulb membranes. 9-TyrO rat/human CRF was incubated for 120 min at room temperature in 50 mM Tris-HCl containing 2 mM EGTA, 1O-4 M bacitracin, 100 kallikrein units/ml aprotinin, pH 7.2, and varying concentrations of MgCI, (triangles), CuClz (squares), and NaCl (circles). Each point is the average of 3 or 4 determinations, which varied by less than 10%. Pharmacological characteristics of the binding site were examined by determining the relative potencies of a variety of CRF-related and unrelated peptides in displacing specifically bound Y-rCRF. The results of these studies are summarized in Figure 9 and Table 2 . Rat CRF was slightly more potent than the ovine analog in displacing the iodinated ligand; the inhibitory binding-affinity constant (KJ values for rat and ovine CRF were 1 and 2.5 nM, respectively. Acetylated ovine CRF (4-41), a fragment more potent than the endogenous ligand in stimulating ACTH release, exhibited a slightly higher affinity (Ki = 0.5 nM) for the lZ51-rCRF binding site, whereas ovine CRF (l-39), a fragment with lOOO-fold lower potency in the ACTH bioassay, was approximately 1000 times less potent than the endogenous ligand in displacing 1251-rCRF from its binding site. The putative weak CRF antagonist, alpha-helical CRF (9-4 l), displaced the 1251-rCRF with a K, value of approximately 15 nM.
A variety of biologically inactive CRF fragments representing the amino terminus ], the carboxy terminus [rCRF (21-41)], and the middle portion [rCRF (6-33)] of the active peptide were found to have no effect on *251-rCRF binding. Equally ineffective in displacing lZ51-rCRF binding were the unrelated peptides angiotensin II, arginine vasopressin, vasoactive intestinal peptide, and an analog of growth hormone-releasing Efects of nucleotides and magnesium on 'z51-rCRF binding Guanine nucleotides have been shown in a number of receptor cyclase-coupled systems to selectively decrease the affinity of agonists for their receptors. By contrast, magnesium ions are thought to enhance agonist binding to adenylate cyclase-coupled receptors by stabilizing the high-affinity form of the receptoreffector complex. To determine whether CRF receptors in brain might be coupled to adenylate cyclase, we carried out a series of studies to examine the effects of magnesium ions and nucleotides on lZSI-rCRF binding in rat olfactory bulb. The addition of increasing concentrations of GTP to the incubation medium resulted in an inhibition of 1251-rCRF binding; the nonhydrolyzable GTP analog GppNHp was even more potent (Fig.  10) . This effect appeared to be specific to the guanine nucleotides, as similar experiments indicated that equimolar concentrations of ATP had no effect on IWrCRF binding (data not shown). GTP and GppNHp inhibited a maximum of 50% of the specific 1251-rCRF binding. Conversely, as mentioned previously, magnesium ions appeared to be obligatory for obtaining significant '251-rCRF binding in olfactory bulb, specific '251-rCRF binding increased in a linear fashion with increasing concentrations of MgCl, (Fig. 3) . To determine whether the effects of guanine nucleotides and magnesium ions were mediated by changes in receptor density or affinity, we carried out a series of parallel L251-rCRF-saturation assays in the presence of 1 and 10 mM MgCl, and 200 I.~M NaGTP. The Scatchard analysis of these saturation data is presented in Figure 11 . GTP increased the apparent Kd of *251-rCRF by 35%; this decrease in affinity . RP-HPLC profile of lz51-Tyro rat/human CRF: Effects of incubation with rat olfactory bulb membranes. Crude mitochondriakynaptosomal membranes were incubated under standard assay conditions with 1251-Tyr0 rat/human CRF for 120 min at room temperature. The reaction was terminated by centrifugation at 12,000 x g for 3 min. Aliquots of 1251-Tyr0 rat/human CRF in the medium before and after, and a 20°h acetonitrile in 0.1% trifluoroacetic acid extract of the tissue-bound radioactivity were analyzed by RP-HPLC using conditions described in Materials and Methods. The elution profile of unlabeled rat CRF was determined by absorbance at 220 nm. For symbols, see inset. The data shown are from a representative experiment. Each value is the average of 3 determinations, which varied by less than 10%. was accomplished by a small ( 10%) reduction in the B,,, value. Conversely, the effect of magnesium on increased rZSI-rCRF binding was accomplished by decreasing both the Kd (50% decrease, from 1 mM to 10 mM MgCl,) and the number of binding sites (Fig. 11) . These results are consistent with the characteristic effects of adenylate cyclase modulators on agonist binding to receptors mediating their effects through CAMP production.
Regional distribution of lZ51-rCRF binding sites in rat CNS Equilibrium-binding parameters, determined from Scatchard plots of competition experiments using unlabeled rCRF and membranes prepared from different CNS regions, indicated generally uniform Kd values but a heterogeneous distribution of 1251-rCRF binding sites across 11 rat CNS regions (Fig. 12) . The Peptides at 3-12 concentrations competed with 30-50 PM fi251-Tv rat/human CRF during a 120 min incubation at room temperature. All assays were conducted in triplicate for the number of experiments in parentheses, and the & (inhibitory binding-affinity constant) and Hill coefficient (mean f SEM) values were obtained from competition curve data analyzed by the computer program EBDA (McPherson, 1983) , which provided initial estimates of the equilibtiumbinding parameters. The bioassay data were obtained from previous studies by Rivier et al. (1982 Rivier et al. ( , 1983 Rivier et al. ( , 1984 . rCRF, Rat corticotropin-releasing factor; oCRF, ovine corticotropin-releasing factor; AVP, arginine vasopressin; VIP, vasoactive intestinal peptide; GRF, growth hormone-releasing factor. highest density of binding sites in the rat CNS was in the olfactory bulb. The density of anterior pituitary binding sites (approximately 2.5 times that of olfactory bulb) is included to indicate the relative abundance of brain binding sites in comparison with this tissue, more commonly employed in CRF binding and bioassays. High levels of lZ51-rCRF binding sites were detected in olfactory bulb, cerebellum, cortex, and striaturn. Progressively lower but significant receptor densities were observed in cervical spinal cord, hypothalamus, medulla, midbrain, thalamus, pons, and hippocampus.
Discussion
In the present study, we have examined the influence of various incubation parameters on 12SI-rCRF binding in rat olfactory bulb membranes. lZSI-rCRF binding was dependent on time and temperature, was sensitive to the pH, ionic strength, and cationic composition of the incubation buffer, and was linear with membrane protein concentration. Receptor binding was optimal in 50 mM Tris-HCl buffer, pH 7.2, and was maximal at room temperature for 90-180 min, with minimal degradation of the radioiodinated peptide occurring under these conditions. The binding of Y-rCRF was saturable, reversible, and of high affinity (K., of 190 PM). lZSI-rCRF binding sites were localized primarily to a tissue preparation that was rich in synaptic membranes. The binding sites for Y-rCRF in rat olfactory bulb membrane preparations exhibit a pharmacological specificity for CRF analogs and fragments that correlates extremely well with their relative intrinsic potency in stimulating or inhibiting anterior pituitary secretion of ACTH in vitro (see Table 2 ). The specificity of the lZ51-rCRF binding site is further strengthened by the lack of inhibitory activity of peptides such as angiotensin II, arginine vasopressin, and vasoactive intestinal peptide, all of which have been shown to also stimulate ACTH secretion through their own respective receptors (Vale and Rivier, 1977; Steele et al., 198 1; Westendorf et al., 1983) . The kinetic and pharmacological characteristics of the LZ51-rCRF binding sites in rat olfactory bulb were comparable to the characteristics found in the other brain regions examined and are similar to those previously observed in rat (Wynn et al., 1983; De Souza et al., 1984a; Holmes et al., 1984) , bovine (De Souza et al., 1984a; De Souza and Kuhar, 1986a, b) and human pituitary and in rat (De Souza et al., 1984b , 1985a Wynn et al., 1984; Chen and Bilezikjian, 1985; De Souza and Kuhar, 1986a, b) and human (De Souza et al., 1986) brain using a variey of ligands. These data substantiate earlier suggestions (Peterfreund and Valentino et al., 1983; Britton et al., 1984) that some structural requirements for CRF activity are shared by brain and pituitary receptors.
Monovalent cations had no effect on lZSI-rCRF binding over the range of concentrations examined, whereas divalent cations such as CaCl, and MgCl, increased binding affinity. The effects of MgCl, on the binding of 1251-rCRF are consistent with previous data demonstrating the ability of magnesium ions to enhance agonist binding to receptors coupled to adenylate cyclase (DeLean et al., 1980) . Likewise, the ability of guanine nucleotides to inhibit 1Z51-rCRF binding is consistent with the hypothesis that receptors for CRF are coupled to adenylate cyclase. There are recent studies reporting the ability of CRF to stimulate adenylate cyclase activity in some brain areas (Wynn et al., 1984; Chen and Bilezikjian, 1985) ; however, there are brain regions with abundant CRF receptors that lack CRF-stimulated adenylate cyclase activity (Chen and Bilezikjian, 1985) . These data imply that CRF-induced signal transduction may be mediated by additional second messengers or by inhibition of adenylate cyclase, as reported for other systems. For example, cholinergic muscarinic agonists have been shown to inhibit CAMP formation as well as to stimulate phosphoinositide metabolism (Brown and Brown, 1984) while dopaminergic agonists have been shown to mediate both the stimulation and inhibition of adenylate cyclase activity through distinct dopaminergic receptor subtypes (Kebabian and Calne, 1979; Creese et al., 1983) . Recently, guanine nucleotides have been shown to also reduce binding of agonists to receptors that mediate their effects through phosphoinositide metabolism (Cockcroft and Gomperts, 1985) . Thus, sensitivity of lZSI-rCRF binding to guanine nucleotides does not preclude the possibility that CRF receptors may also be coupled to phosphoinositide metabolism. Given suggestions that there might be more than 1 class of binding site for CRF in brain in this and other reports (Chen and Bilezikjian, 1985; De Souza et al., 1985a; De Souza and Kuhar, 1986a) , it would be ofinterest to examine in greater detail the roles of other transduction mechanisms, in addition to CRF-stimulated adenylate cyclase, in mediating the actions of CRF, such studies are currently under way in our laboratory.
The results of the present study confirm the presence and heterogeneous distribution of specific, high-affinity receptors for CRF throughout the rat CNS. The highest densities of 1251-rCRF Effects of magnesium ions and guanosine-5'-triphosphate (GTP) on the binding of lz51-TyrO rat/human CRF to rat olfactory bulb membranes. Scatchard plots of the lZ51-Tyr0 rat/human CRF binding to crude mitochondrial/synaptosomal membranes in the presence of 1 mM MgCl*, IO mM MgC&, or IO mM MgC& plus 200 /LM GTP and increasing concentrations of ligand (0.05-l nM). Incubations were for 120 min at room temperature. Nonspecific binding was in the presence of 1 PM rat CRF. The concentration of free 1251-Tyr0 rat/human CRF was measured directly in aliquots of the supematant after the binding reaction was terminated by centrifugation. Points are the means of triplicate determinations in a representative experiment.
binding sites were detcted in olfactory bulb, cerebellum, cerebral cortex, and striatum, with progressively lower but significant receptor densities present in spinal cord, hypothalamus, medulla, midbrain, thalamus, pans, and hippocampus. In general, the distribution of CRF binding sites at the gross level of these homogenate binding assays correlates well with previous data from higher-resolution autoradiographic localization studies (De Souza et al., 1984b , 1985a Wynn et al., 1984; De Souza and Kuhar, 1986a, b) . Centrally administered CRF produces a broad spectrum of autonomic and behavioral effects, including increases in plasma levels of catecholamines (Brown et al., 1982) and glucose (Brown et al., 1982) , increases in cardiovascular parameters, including heart rate and mean arterial pressure (Fisher et al., 1983 ) altered gastric acid secretion (Tache et al., 1983 ) and a variety of behavioral changes associated with general arousal, such as increased locomotor activity in familiar surroundings (B&ton et al., 1982 Sutton et al., 1982; Veldhuis and De Wied, 1984) , increased "emotionality" in a novel environment (B&ton et al., 1982 Sutton et al,. 1982; Veldhuis and De Wied, 1984) , and decreases in feeding (Morley and Levine, 1982) and sexual (Sirinathsinghji et al., 1983) behaviors. In addition, numerous areas of the brain, including the cortex, hypothalamus, thalamus, and lateral septal area have been shown to be electrophysiologically responsive to iontophoretic application of CRF (Eberly et al., 1983) , as Relative values represent the mean + SEM determined from results of 3-5 experiments comparing the levels of IZ51-Tyr" rat/human CRF binding in the absence (total) and presence (blank) of 1 PM rat CRF across all regions and 3-5 experiments in which regional competition curves using increasing concentrations of unlabeled rat CRF were analyzed by EBDA to obtain B,, values.
have discrete brain stem areas, much as the locus coeruleus and parabrachial nucleus (Valentino et al., 1983) . Hippocampal slice preparations have been employed to demonstrate the electrophysiological effects of CRF in vitro (Aldenhoff et al., 1983) , and intracerebroventricular administration of high doses of CRF has been shown to elicit epileptiform seizures that appear, on the basis of associated electroencephalographic patterns, to originate in the amygdala (Ehlers et al., 1983) . It is likely that the diversity of physiological and behavioral responses to CRF, in conjunction with the variety of areas that are electrophysiologically responsive to this peptide, would demand a correspondingly broad anatomical distribution of receptors for CRF in the CNS.
In contrast to the good correlation between regional levels of binding sites for 'Y-rCRF in these homogenate binding assays, and the localization of CRF receptors by light-microscopic autoradiography, there are areas in the rat CNS in which the presence of high concentrations of CRF receptors does not correspond to the reported distribution of CRF-immunoreactive (CRF-IR) fibers. Primary examples of this disparity involve the olfactory bulb and cerebellum. In the rat cerebellum, moderate (Cummings et al., 1983) , low (Olschowka et al., 1982) , and undetectable densities of CRF-IR fibers have been reported, while the second highest concentration of 1251-rCRF binding sites in the CNS was detected in this brain region. Similarly, the olfactory bulb has the highest concentration of CRF receptors in the CNS, but only low concentrations of olfactory bulb CRF-IR have been reported . Similar mismatches between the levels of transmitter and receptor have been noted in previous studies involving both classical neurotransmitters and neuropeptides (Zarbin et al., 1983; Goedert et al., 1984; Mantyh et al., 1984) , and the "mismatch problem" has been the topic ofa recent report (Kuhar, 1985) . The problem, as it relates to CRF in brain, has been discussed in detail in a recent paper (De Souza et al., 1985a) .
The high density of CRF receptors in the rat olfactory bulb and their distribution throughout the olfactory system are striking. CRF receptors in the rat olfactory bulb have been localized autoradiographically to discrete laminar divisions associated with the termination of primary olfactory afferents and with the origin of olfactory efferent axons (Wynn et al., 1984; De Souza et al., 1985a; De Souza and Kuhar, 1986b) . There is evidence in the literature suggesting that sexual, reproductive, social, and feeding behaviors of most mammalian species are mediated by olfactory substances and pheromonal agents acting through the olfactory system (see Whitten and Bronson, 1970) . CRF influences both feeding behavior and sexual activity. Although the hypothalamus is the primary anatomical locus regulating sexual activity and feeding behavior, hypothalamic neuronal activity can be modulated by olfactory impulses relayed through the circuit involving the olfactory bulb, pyriform cortex, amygdala, and subiculum; moderate to high densities of CRF are present throughout the circuit (De Souza et al., 1985a) . In rats, olfactory bulbectomy serves as a good model for the study of many of the manifestations seen in clinical depression (Leonard and Tuite, 198 1); altered CRF concentrations in the CSF (Nemeroff et al., 1984) and adrenocorticotropic hormone response to CRF (Gold et al., 1984) have been reported in depressed patients.
Thus, while the role of CRF in olfactory-mediated behaviors is, at present, unknown, the presence of high concentrations of receptors throughout the olfactory system may suggest a functional role for CRF in mediating these influences. In the rat neocortex, CRF cell bodies are concentrated in laminae II and III, with projections to laminae I and IV (Olschowka et al., 1982; Cummings et al., 1983; Swanson et al., 1983) areas rich in CRF receptors (De Souza et al., 1984b , 1985a Wynn et al., 1984; De Souza and Kuhar, 1986a, b) . The biological relevance of CRF receptors in the cerebral cortex is supported by the observation that CRF stimulates secretion of somatostatin from dispersed rat cerebral cortical cells (Peterfreund and . Very recently, we found that in Alzheimer's disease the concentrations of CRF-IR were reduced and there were reciprocal increases in the number of 1251-rCRF binding sites in affected areas of the cerebral cortex (De Souza et al., 1986) . These data from human cortex (De Souza et al., 1986) (Olschowka et al., 1982; Cummings et al., 1983; Swanson et al., 1983) . Although low to moderate concentrations of L251-rCRF binding sites are found in homogenates of whole hypothalamus, previous autoradiographic data have localized CRF receptors at moderate to high concentrations in the PVN and median eminence, respectively (De Souza et al., 1984 , 1985a , b, De Souza and Kuhar, 1986a . The CRF binding sites in these hypothalamic areas may represent presynaptic autoreceptors or receptors for interneuronal communication that may play important roles in regulating peptide release. The hypothalamus may also be a primary site of action for integrating the endocrine, autonomic and behavioral effects of CRF. Microinfusions of CRF into the hypothalamus suppress sexual behavior (Sirinathsinghji et al., 1983) . In addition, intracerebroventricular injections of CRF have been shown to inhibit the release of growth hormone (Ono et al., 1984; Rivier and Vale, 1984b) , luteinizing hormone (Ono et al., 1984; Rivier and Vale, 1984b) , vasopressin, and oxytocin (Plotsky et al., 1985) and to have deleterious effects on reproductive functions . CRF can also stimulate the secretion of somatostatin by cultured rat hypothalamic cells (Peterfreund and Vale, 1983) . In summary,
we have used an iodine-12%labeled analog of the endogenous ligand to identify, characterize, and localize receptors for CRF in discrete areas of the rat CNS. The effects of guanine nucleotides in decreasing and of magnesium ions in increasing 1251-rCRF binding are consistent wth data demonstrating that some populations of CRF receptors are coupled to adenylate cyclase; however, whether there are additional CRFmediated signal transduction mechanisms remains to be determined. These data provide further support for the proposed role of CRF as a neurotransmitter in the CNS. This study demonstrating the characteristics of CRF receptors in brain provides a means for better understanding the various functions of this neuropeptide under physiological and pathological conditions.
